Researchers successfully used a noninvasive broadband optical spectroscopy (BOS) device to detect necrotizing enterocolitis (NEC) early in premature infants.
Key Details
- 1BOS is a handheld device that measures reflected infrared light from the intestines to detect early NEC.
- 2The technology distinguishes NEC from healthy tissue within two minutes at the bedside.
- 3First-in-human study tested BOS on 96 premature infants younger than 36 weeks gestation.
- 4BOS produced safe, feasible, and detectable signal changes in infants with NEC.
- 5BOS may identify NEC before it appears on x-ray; prior x-ray is the current standard diagnostic tool.
Why It Matters
BOS could allow bedside, early, radiation-free detection of NEC—a life-threatening disease—enabling earlier treatment and potentially improving outcomes in neonates. The move toward new optical imaging modalities may supplement or even precede conventional radiology tools like x-ray in this clinical scenario.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.